Skip to main content
Article
Using prophylactic antihemorrhagic medications in second-trimester surgical abortions
Obstetrics and gynecology
  • Kelly Fairchild, Advocate Aurora Health
  • Morgan Altinok, Advocate Aurora Health
  • Jessica J Kram, Advocate Aurora Health
  • Kayla Heslin, Advocate Aurora Health
  • Michelle Montgomery, Advocate Aurora Health
  • Elizabeth Dickson Michelson, Advocate Aurora Health
  • Benjamin Dorton, Advocate Aurora Health
Affiliations

Aurora University of Wisconsin Medical Group, Aurora Sinai Medical Center, Advocate Aurora Research Institute, Aurora West Allis Medical Center

Scholarly Activity Date
10-1-2022
Abstract

We aimed to estimate the association of prophylactic antihemorrhagic medication use during dilation and evacuation (D&E) with operative hemorrhage and estimated blood loss (EBL). Records for all pregnant patients between 14 and less than 22 weeks of gestation who had a D&E procedure from January 2012 to December 2019 were retrospectively reviewed. Prophylactic antihemorrhagic medication use was defined as receiving vasoconstrictors, uterotonics, or both before identification of hemorrhage during a D&E procedure. Overall, 147 D&E procedures were completed at a mean of 16.4 (±2.2) weeks of gestation. Prophylactic medications were used in 72.1% (n=106) of D&E procedures. Prophylactic medication use was associated with lower operative hemorrhage (21.7% vs 51.2%, P < .01) and lower EBL (336.9 mL vs 551.3 mL, P < .01).

Type
Article
PubMed ID
36075063
Citation Information

Fairchild K, Altinok M, Kram JJF, et al. Using Prophylactic Antihemorrhagic Medications in Second-Trimester Surgical Abortions. Obstet Gynecol. 2022;140(4):663-666. doi:10.1097/AOG.0000000000004922